Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
LENZ Therapeutics (LENZ)
NASDAQ:LENZ
Holding LENZ?
Track your performance easily
LENZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.07 - $29.82
Previous Close$21.5
Volume140.59K
Average Volume (3M)172.12K
Market Cap
$591.18M
Enterprise Value$396.12M
Total Cash (Recent Filing)$196.11M
Total Debt (Recent Filing)$1.05M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
May 07, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 22, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-9.44
Shares Outstanding27,496,665
10 Day Avg. Volume175,772
30 Day Avg. Volume172,116
Standard Deviation0.22
R-Squared0.01
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)3.06
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-9.03
Forecast
1Y Price Target
$33.80Price Target Upside53.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
LENZ Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial Results84% of participants taking LNZ100 achieved at least 4 lines of near-vision improvement, significantly outperforming the vehicle group.
Market OpportunityThe presbyopia market represents a significant opportunity with a high unmet need for an effective eyedrop treatment.
Product DifferentiationLenz is the sole developer of aceclidine-based drops for presbyopia, offering a unique approach over competitors.
Bears Say
CompetitionThere are multiple marketed/late-stage competitors that could take presbyopia market share.
Market PerceptionLenz will have to overcome negative perceptions of presbyopia eye drops.
Market ShareCompetition from multiple marketed and late-stage competitors could impact Lenz's market share in the presbyopia treatment market.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LENZ FAQ
What was LENZ Therapeutics’s price range in the past 12 months?
LENZ Therapeutics lowest stock price was $14.07 and its highest was $29.82 in the past 12 months.
What is LENZ Therapeutics’s market cap?
Currently, no data Available
When is LENZ Therapeutics’s upcoming earnings report date?
LENZ Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 229 days.
How were LENZ Therapeutics’s earnings last quarter?
LENZ Therapeutics released its earnings results on Aug 14, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.479 by $0.079.
Is LENZ Therapeutics overvalued?
According to Wall Street analysts LENZ Therapeutics’s price is currently Undervalued.
Does LENZ Therapeutics pay dividends?
LENZ Therapeutics pays a Notavailable dividend of $1.03 which represents an annual dividend yield of N/A. See more information on LENZ Therapeutics dividends here
What is LENZ Therapeutics’s EPS estimate?
LENZ Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LENZ Therapeutics have?
LENZ Therapeutics has 27,496,664 shares outstanding.
What happened to LENZ Therapeutics’s price movement after its last earnings report?
LENZ Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.479. Following the earnings report the stock price went down -3.83%.
Which hedge fund is a major shareholder of LENZ Therapeutics?
Among the largest hedge funds holding LENZ Therapeutics’s share is RA Capital Management. It holds LENZ Therapeutics’s shares valued at 72M.
---
LENZ Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.80 (53.08% Upside)
$33.80 (53.08% Upside)
Hedge Fund Trend
Increased
By 17.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.08%
12-Months-Change
Fundamentals
Return on Equity
-34.67%
Trailing 12-Months
Asset Growth
-29.40%
Trailing 12-Months
Company Description
LENZ Therapeutics
LENZ Therapeutics is a late-stage clinical company headquartered in San Diego, California. The company is primarily focused on developing and commercializing the first aceclidine-based eye drop designed to improve vision in patients with presbyopia. Presbyopia is a common vision disorder affecting people as they age. The company aims to address the growing global demand for treatments in ophthalmology, particularly for aging populations.
---
LENZ Stock 12 Month Forecast
Average Price Target
$33.80
▲(53.08% Upside)
Technical Analysis
Best Analysts Covering LENZ
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+11.68%
reiterated a buy rating last month
Copying Marc Goodman's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +11.68% per trade.
---